An interventional study of Alert-based computerized decision support in Familial Hypercholesterolaemia, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 15th largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 70th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Wisconsin, Madison · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 6–17
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 20 more countries
Ages 6–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 34 · Phase 4 4
First in 1985; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 163 across the 68 interventional studies, 22 across the 8 observational. Of the 57 that completed or were terminated, 32 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 76 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,269 studies on the registry; 230 are open to participants now.
Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 1 study filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperlipoproteinemia Type II with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05284513Geisinger ClinicCollaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH) | 2027-01 |
| NCT05750667Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia | 2027-02-28 |
| NCT07919353Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3 | 2027-02-28 |
| NCT06743659Brigham and Women's HospitalComputerized Decision Support for Identification and Management of Familial Hypercholesterolemia | 2027-03-30 |
| NCT06439654Atlantic Health SystemAtlantic Lipid Lowering Treatment Optimization Program | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if a computer alert can aid clinicians in identifying patients with a genetic type of high cholesterol, called Familial Hypercholesterolemia. The main question it aims to answer is whether the computer alert increases recognition of this high cholesterol disorder.
FH-ALERT is a single-center, time-series trial of a patient- and provider-facing EPIC BPA (alert-based CDS tool) to increase diagnosis, LDL-C lowering, and guideline-based therapy of outpatients with presentations consistent with FH. For the first 6 months, the BPA will run in "silent mode", identifying patients with presentations consistent with FH, but not alerting the clinician of record. Following this initial "pre-alert" 6-month period, the BPA will switch to "alert mode" for 18 months, which will provide the on-screen notification to the clinician of record. In other words, consecutive outpatients with presentations consistent with FH will be enrolled over two years: "pre-alert" (silent mode) for 6 months and "alert mode" for 18 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In the Pre-Alert phase of 6 months, patients meeting enrollment criteria will be identified but the clinician will not be notified regarding the possible diagnosis of Familial Hypercholesterolemia.
In the Alert phase of 18 months, an on-screen alert through the Electronic Health Record will notify the ambulatory care clinician of record that the patient has a "definite," "probable," or "possible" diagnosis of FH but has not been recognized as such.
Device: Alert-based computerized decision support
A program will be designed to run within the Electronic Health Record (EHR) that will identify outpatients with "definite," "probable," or "possible" diagnosis of FH. The BPA will calculate the Dutch Lipid Clinic Network score using the following EHR data: 1. Maximum LDL-C level in the laboratory results 2. Abnormal genetic testing for FH in the laboratory results 3. Medical history or problem list entry for tendinous xanthomata or arcus cornealis 4. Medical history, visit diagnosis, or problem list entry of premature CAD, cerebrovascular disease, or PAD 5. Family history of premature CAD, cerebrovascular disease, or PAD In the Alert phase, an on-screen alert will notify the ambulatory care clinician of record that the patient has a "definite," "probable," or "possible" diagnosis of FH. ambulatory care clinician will have the opportunity to proceed to an order template through which a referral for specialty care focused on evaluation and management of FH can be made.
Also known as: Best Practice Advisory, Computer Alert
Frequency of documented FH diagnosis
We will review the medical history, visit diagnosis, and problem list sections of the Electronic Health Record (EPIC) to make this determination of diagnosis of Familial Hypercholesterolemia.
Time frame: 6 Months
Mean Change in LDL-C
Mean change in LDL-C levels within 6 months following triggering of the BPA compared with the most recent LDL-C prior to the clinic visit in outpatients with presentations consistent with FH ("definite," "probable," or "possible" Dutch Lipid Clinic Network score).
Time frame: 6 Months
Plan to share: Yes — Will provide data upon reasonable request after publication of study.
Supporting information: Study protocol, Clinical study report, Analytic code
Time frame: After completion of the study for a period of 10 years
Access criteria: Investigators with a scientifically sound reason for accessing the data upon reasonable request
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
Of 35 non-industry interventional studies with no phase under Hyperlipoproteinemia Type II, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 23 months is below that.
Counting every sponsor, half of 37 studies reached it within 29 months; a quarter within 12 and three quarters within 41.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Nov 2027, on Sep 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type II →
Brigham and Women's Hospital →